BIOGEN INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 218.1 USD | -3.17% |
|
-5.21% | -15.73% |
| May. 22 | US Equity Markets Close Down Wednesday After Fed Minutes Raise Inflation Concerns | MT |
| May. 22 | Sector Update: Health Care Stocks Slightly Higher Late Afternoon | MT |
Financials (USD)
| Sales 2024 * | 9.52B | Sales 2025 * | 9.56B | Capitalization | 32.79B |
|---|---|---|---|---|---|
| Net income 2024 * | 1.9B | Net income 2025 * | 2.21B | EV / Sales 2024 * | 3.76 x |
| Net Debt 2024 * | 3.01B | Net Debt 2025 * | 536M | EV / Sales 2025 * | 3.49 x |
| P/E ratio 2024 * |
17.1
x | P/E ratio 2025 * |
14.8
x | Employees | 7,570 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 85.81% |
More Fundamentals
* Assessed data
More news
Latest transcript on Biogen Inc.
More recommendations
More press releases
More news
| 1 day | -2.64% | ||
| 1 week | -5.06% | ||
| Current month | +1.67% | ||
| 1 month | +13.06% | ||
| 3 months | -2.20% | ||
| 6 months | -5.84% | ||
| Current year | -15.60% |
1 week
217.21
232.75
1 month
198.11236.90
Current year
189.44268.30
1 year
189.44319.76
3 years
187.16468.55
5 years
187.16468.55
10 years
187.16480.18
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 64 | 22-11-13 | |
| Director of Finance/CFO | 60 | 20-08-14 | |
Nicole Murphy
COO | Chief Operating Officer | - | 14-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Stephen Sherwin
BRD | Director/Board Member | 75 | 09-12-31 |
William Hawkins
BRD | Director/Board Member | 70 | 19-06-18 |
Caroline Dorsa
CHM | Chairman | 64 | 10-01-02 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 4.30% | 1 M€ | 0.00% | - | |
| 3.92% | 0 M€ | 0.00% | - | |
| 3.75% | 0 M€ | 0.00% | - | |
| 2.39% | 13,519 M€ | +6.64% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-23 | 218.1 | -3.17% | 1 068 644 |
| 24-05-22 | 225.2 | -1.09% | 1,225,658 |
| 24-05-21 | 227.7 | -1.68% | 761,248 |
| 24-05-20 | 231.6 | +0.44% | 719,121 |
| 24-05-17 | 230.6 | +0.23% | 985,059 |
Delayed Quote Nasdaq, May 23, 2024 at 10:58 am EDT
More quotes
Biogen Inc. is one of the world's leaders in the design, manufacturing, and marketing of therapeutic products. Net sales break down by source of income as follows:
- sales of medicines (73,7%): for treating multiple sclerosis, chronic psoriasis in adults, rheumatoid arthritis, cancers, etc.;
- royalties (17,2%) ;
- other (9,1%): primarily revenues from partnership agreements.
Sector
Pharmaceuticals
Calendar
2024-06-20
- Annual General Meeting
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
BUY
Number of Analysts
33
Last Close Price
225.2
USD
Average target price
287.3
USD
Spread / Average Target
+27.57%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -15.60% | 32.79B | |
| -1.62% | 89.22B | |
| +2.24% | 40.49B | |
| +63.43% | 26.23B | |
| -22.11% | 14.52B | |
| -7.92% | 13.09B | |
| -42.60% | 11.6B | |
| -12.64% | 11.5B | |
| +5.24% | 8.82B | |
| -13.45% | 7.92B |
- Stock Market
- Equities
- BIIB Stock
